Stock Information
CorMedix Inc (CRMD)
Ticker Symbol: CRMD
Exchange: NASDAQ
Sector: Pharmaceuticals
Market Cap: $555.46 mil
Piotroski score: 2
PE Ratio: 3.6507
EPS (TTM): 1.983
Revenue (TTM): $3.31 M
Dividend Yield: N/A%
ROE: 58.5%
Latest News
-
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14
Tue, Apr 28, 2026 10:17 AM
-
Citizens Reiterates Market Outperform on Cormedix, Maintains $19 Price Target
Tue, Apr 28, 2026 9:46 AM
-
Leerink Partners Maintains Outperform on Cormedix, Raises Price Target to $14
Tue, Apr 28, 2026 8:56 AM
-
CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study
Mon, Apr 27, 2026 1:00 PM
-
Needham Maintains Buy on Cormedix, Raises Price Target to $15
Mon, Apr 27, 2026 12:26 PM
-
Cormedix Therapeutics announces positive topline results from phase III Respect trial
Mon, Apr 27, 2026 8:40 AM
-
CorMedix Announces Phase III Topline Results From Global ReSPECT Clinical Trial Evaluating REZZAYO For Prophylaxis Of IFDs In Adult Patients Undergoing Allogeneic HSCT; Study Meets Primary Endpoint
Mon, Apr 27, 2026 7:33 AM
-
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
Mon, Apr 27, 2026 7:30 AM
Key Financials
Financial data not available
